Innova Captab Limited — Investor Meet, 14-05-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Innova Captab achieved record FY'26 revenue of INR1,630 Cr (+31% YoY), with Q4 revenue up 42% YoY to INR448 Cr. Both CDMO (+24%) and Branded Generics (+51%) powered this growth. FY'26 EBITDA was INR250.3 Cr (15.4% margin); PAT grew 10% to INR140.9 Cr. The Jammu facility contributed INR300 Cr, nearing EBITDA breakeven. Management anticipates 20%+ revenue growth, with operating leverage driving EBITDA and PAT faster. Key regulatory approvals (UK-MHRA, PIC/S) obtained. A new Baddi plant (INR150-170 Cr capex) is planned to expand oral formulation capacity. Semaglutide is being monitored for a 'wave 2' launch, supporting a confident outlook for sustained growth.